Abstracts

ENPATORAN SAFETY AND EFFICACY IN COVID-19 PNEUMONIA: ANEMONE TRIAL

Enpatoran, a selective and potent toll-like receptor 7 and 8 (TLR7/8) inhibitor, is in development for treating autoimmune diseases. Enpatoran may prevent hyperinflammation and cytokine storm in COVID-19 by targeting pro-inflammatory pathways induced by SARS-CoV-2. The ANEMONE study, a phase II, randomized, double-blind, placebo-controlled trial conducted in the US, the Philippines, and Brazil, assessed the…

IMPACT OF TENOFOVIR ON SARS-CoV-2 INFECTION AMONG PEOPLE LIVING WITH HIV

The impact of some antiretrovirals against SARS-CoV-2 infection and disease severity is conflicting. We evaluated the effect of tenofovir alafenamide/emtricitabine (TAF/FTC) and tenofovir disoproxil fumarate/emtricitabine (TDF/FTC) against SARS-CoV-2 infection and associated clinical outcomes among people living with (PLWH). We conducted a propensity score-matched analysis leveraging data from the PISCIS cohort of PLWH in Catalonia (Spain).…

MOLNUPIRAVIR INCREASES RANDOM SARS-CoV-2 RNA ERRORS WITHOUT SELECTION FOR RESISTANCE

Molnupiravir (MOV), the orally administered prodrug of the antiviral ribonucleoside analogue, N-hydroxycytidine (NHC) has received emergency use authorization for treatment of COVID-19. NHC inhibits viral replication by introduction of random transition errors across the viral genome, resulting in non-infectious virus. In the Phase 2/3 (MOVe-OUT) study, non-hospitalized participants received MOV or placebo (PBO) for 5…

GUNNERA PERPENSA ELLAGITANNINS SYNERGISTICALLY INHIBIT MULTIPLE SARS-CoV-2 VARIANTS

Antivirals are urgently needed to supplement SARS-CoV-2 vaccines and target SARS-CoV-2 variants of concern, particularly in resource-limited regions. Active derivatives from the medicinal plant Gunnera perpensa, already in use as a general antiviral in humans by traditional health practitioners in the Eastern Cape Province of South Africa, warrant further evaluation against SARS-CoV-2. Active constituents of…

INTERIM ANALYSIS OF A PHASE I STUDY OF PRTX007: SAFETY, PK, AND PD RESPONSE

PRTX007 is a prodrug of PRX034, a novel TLR7 agonist, for treatment of respiratory viral diseases including SARS-CoV-2. PRX034 activates plasmacytoid dendritic cells to preferentially synthesize poly sub-type interferons while minimizing NF??-mediated proinflammatory factors. Pre-clinical studies have demonstrated decoupling of these two normally linked processes in human PBMCs in vitro and in cynomolgus monkeys in…